𝔖 Bobbio Scriptorium

✦ LIBER ✦

A software for registration and stratified randomization in multicenter clinical trials: The experience of the European lung cancer working party

✍ Scribed by M. Paesmans; F. Moreels; J.P. Sculier

Book ID: 113297641
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 90 KB
Volume: 13
Category: Article
ISSN: 0197-2456
DOI: 10.1016/0197-2456(92)90170-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A59 Development of a software using a to

A59 Development of a software using a touch tone phone system and a vocal interface for automatic registration and randomization in multicenter clinical trials: Further experience of the European lung cancer working party

✍ M. Paesmans; F. Moreelsand; J.P. Sculier 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 88 KB

Final results and pharmacoeconomic analy

Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomised study by the European Lung Cancer Working Party

✍ Berghmans, T.; Lafitte, J.J.; Giner, V.; Berchier, M.C.; Scherpereel, A.; Lewin, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 337 KB

Early results of a randomized phase III

Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non–small cell lung cancer: European Organization for Research and Treatment of Cancer 08975

✍ Giuseppe Giaccone 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

First results of a randomized phase III

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

✍ R Paridaens; P Therasse; L Dirix; L Beex; M.J Piccart; D Cameron; T Cufer; K Roo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB